Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 13, 2022
Discovery & Translation
Aro’s protein-siRNA conjugate for Pompe disease; plus Rheos, Mozart and more
BioCentury’s roundup of translational news
BioCentury | Apr 22, 2021
Emerging Company Profile
Monopteros: Medicxi-backed start-up believes MALT1 inhibition can prime tumors for checkpoint blockade
Emerging Company Profile: Monopteros’ $20M round to support Phase I/Ib trial, first in solid tumors
BioCentury | Jun 20, 2019
Translation in Brief
Turning Tregs against cancer
Reprogramming immunosuppressive Tregs to inflammatory cells could enhance checkpoint inhibition therapy
BioCentury | Jun 11, 2019
Distillery Therapeutics
CARD11, MALT1 inhibition sensitizes melanoma, colorectal tumors to PD-1 inhibitors
BioCentury | Mar 1, 2019
Translation in Brief
Targeting pathogenic Th17 cells
How two new autoimmune targets drive pathogenic Th17 activity
BioCentury | Feb 12, 2019
Translation in Brief
Stabilizing mutant proteins
NIBR, UBC’s allosteric MALT1 stabilizers for mutation-driven immunodeficiency
Items per page:
1 - 10 of 21